Silence Therapeutics (SLN) Income towards Parent Company (2020 - 2026)
Silence Therapeutics recorded quarterly Income towards Parent Company of -$15.0 million in Q1 2026, down 16.42% quarter-over-quarter from -$12.8 million in Q4 2025, and up 47.57% year-over-year from -$10.1 million in Q1 2025.
Silence Therapeutics' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$15.0 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 47.57% year-over-year to -$15.0 million; the TTM figure through Mar 2026 stood at -$76.1 million (up 1.69% YoY), while the FY2025 annual figure was -$89.7 million, down 97.95% from the prior year.
- Income towards Parent Company came in at -$15.0 million for Q1 2026 at Silence Therapeutics, down from -$12.8 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $12.3 million in Q4 2024 to a low of -$39.2 million in Q3 2024.
- A 5-year average of -$16.3 million and a median of -$15.4 million in 2023 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company jumped 166.23% in 2024 and slumped 1134.0% in 2025, its largest moves.
- Silence Therapeutics' Income towards Parent Company stood at -$17.7 million in 2022, then slipped by 5.23% to -$18.6 million in 2023, then soared by 166.23% to $12.3 million in 2024, then sank by 204.44% to -$12.8 million in 2025, then slipped by 16.42% to -$15.0 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$15.0 million, -$12.8 million, and -$21.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.96 Mn |
| Dec 31, 2025 | -12.85 Mn |
| Sep 30, 2025 | -20.96 Mn |
| Jun 30, 2025 | -27.35 Mn |
| Mar 31, 2025 | -28.53 Mn |
| Dec 31, 2024 | 12.30 Mn |
| Sep 30, 2024 | -39.18 Mn |
| Jun 30, 2024 | -22.01 Mn |
| Mar 31, 2024 | -2.31 Mn |
| Dec 31, 2023 | -18.58 Mn |
| Sep 30, 2023 | -13.50 Mn |
| Jun 30, 2023 | -15.03 Mn |
| Mar 31, 2023 | -15.40 Mn |
| Dec 31, 2022 | -17.65 Mn |
| Sep 30, 2022 | -10.99 Mn |
| Jun 30, 2022 | -16.90 Mn |
| Mar 31, 2022 | -12.84 Mn |
| Dec 31, 2021 | -15.13 Mn |
| Sep 30, 2021 | -16.61 Mn |
| Jun 30, 2021 | -17.76 Mn |
| Mar 31, 2021 | -13.61 Mn |
| Dec 31, 2020 | -17.39 Mn |
| Sep 30, 2020 | -12.31 Mn |